"The money raised will help us learn more about colorectal cancer."
“We are always ready to welcome new students with a passion for cancer research."
"One of the best things about this drug is that it combines well with nearly everything, it's really a doctor's dream"
“We started this program a couple years ago to give women affected by breast and gynecologic cancers more treatment choices when they think there are no other options”
“My biggest concern is safety because of the lack of oversight and regulation"
A new study shows that women with early stage breast cancer can skip chemotherapy.
The study comes in the context of continuing work to target MET amplification in cancer.
Co-owner Christy Brant’s son Nick Brant is a colon cancer survivor and is under the care of Lieu.
Drs. Chris Lieu and Jennifer Diamond discuss the importance of clinical trials in identifying new ways to prevent, detect and treat cancer.
Thank you for your 13 years of service in the Division of Medical Oncology.
On being awarded the Department of Medicine Rising Star Award!
There are many drugs targeting many genetic changes that are approved for other cancers, which we would not usually think to use in thyroid cancer.
Wells really brought his “A” game and provided clear, concise reviews and suggestions on case management.
On winning the top poster award at the national TL1 Conference in Washington, DC.
On being accepted into the American Society for Blood and Marrow Transplantaion (ASBMT).
She recieved the 2018 HTRS/Novo Nordisk Clinical Fellowship Award in Hemophilia and Rare Bleeding Disorders.
Congratulations to Dr. Jimeno on being selected to join the Developmental Therapeutics Study Section!
On being awarded the “Outstanding Research abstract Award” and the “Research Abstract Merit Award” in this year's DOM Research Day Abstract Competition.
Congratulations to Fashad Chowdhury, MD on receiving two seperate awards.
On being awarded The AACR-Conquer Cancer Foundation for the ASCO Young Investigator Award for Translational Cancer Research
Congratulations to Brianna Hoffner on winning the Nightingale Luminary Award!
Both accepted to attend the End-of-Life Nursing Education Consortium (ELNEC) APRN course in Pasadena, CA in April!
John Tentler, PhD, CU Cancer Center’s associate director for education talks to students about cancer biology
NEJM reports positive results for larotrectinib against TRK-fusion cancers
Congratulations to Antonio Jimeno, his lab and other collaborative partners on receiving the Department of Defense Expansion Award!
Patients with terminal cancer face difficult decisions. What treatment options support their goals? When is it reasonable to discontinue care?
Congatulations to Emily Cox-Martin and D. Ross Camidge!
Daniel Bowles, MD will now be taking on the role of Program Director.
Dr. Leal discusses the importance of a new blood test used to detect 8 different types of cancers.
Congratulations to Dr. James Dugan on becoming Chief Fellow for the 2018-2019 academic year.
However, when all three receptors are present – this “triple-positive” breast cancer – blocking any single receptor is not enough.
“I am not looking to break the law. But I am not looking to die, either,” Keays declared.
Throughout his career, Dr. Bunn has been President of ASCO, IASLC, and AACI, chairman of the FDA Oncology Drug Advisory Committee, and Executive Director of the IASLC.
Chris Lieu, Stephen Leong and Traci Lyons discuss their journeys that led them to their careeers.
Monica Brown and Madison Weber spent their summer doing cancer research.
A plumber, a patient and her doctor help keep research strong in Colorado.
Clinical trials of new anti-cancer therapies have often excluded patients whose disease has spread to the brain or central nervous system (CNS).
“ROS1 we've known about for a long time: It's about 2 percent of lung cancer. It works very well when you give crizotinib (Xalkori),” said D. Ross Camidge, M.D., Ph.D.
“We are delighted to have a scientist of Bob’s caliber leading our program."
Farewell to Anne Leyba. We are so grateful for your many years of service with the University of Colorado.
Patients received a median of two prior HER2-based regimens and the median duration of the last prior treatment in this subgroup was 9.03 months.
A company called Color is helping people learn more about their genes. Specifically, gene mutations that can indicate a higher risk for cancer.
“I think it saved my life,” he said.
“I would agree with that,” said Dr. Jose Mayordomo, Phil’s oncologist at the University of Colorado Hospital.
This is a very incredible honor as only three of nine hundred faculty members were accepted.
Please join us in congratulating Daniel Bowles, MD and Brandon McMahon, MD on their new roles within the Hematology/Oncology Fellowship Program.
It started with his diagnosis of colorectal cancer in July of 2014. Things did not look good his oncologist told him.
“I was diagnosed very, very, late.”
The University of Colorado's Division of Medical Oncology was strongly represented by our talented and deticated APPs at this year's JADPRO Live at APSHO in Houson.
When the group used TAK-228 to block mTOR signaling, instead of becoming senescent, triple-negative breast cancer cells died.
Entrectinib may allow for better upfront control of existing brain metastases, and may prevent the development of brain metastases in the future.
The study finds a genetic change called ALK-fusion in a patient sample of a melanoma subtype called mucosal melanoma.
Nursing has been linked to a reduced risk of breast cancer in both pre- and post-menopausal women.
“We will have a lot of discussion and new data on immunotherapy from several studies, but because we are moving immunotherapy to earlier-stage treatment, that will certainly be discussed.”
Studies show regular exercise can reduce the risk of breast cancer. Orangetheory Fitness & UCH are teaming to help people fight the disease.
We wish the best for Leila in her future projects and will miss her very much as she has been an incredible asset to this Division.
We would like to thank Barbara Helfrich on her 25 years of service with the University and congratulate her on her recent retirement. She will be missed.
Late-Breaking Abstract presentations of phase III trial data give exciting new insights into the future of treatment.
Does any research presented at the European Society of Medical Oncology (ESMO) 2017 Congress inform clinicians how and when to administer PD-1 or PD-L1 therapies?
Congratulations to Antonio Jimeno and his lab!
In recent years, dramatic anti-cancer responses have become possible for some patients with advanced NSCLC with targeted therapies used against specific mutations.
A college baseball coach, battling a rare form of liver cancer, got some encouragement Tuesday from the pros.
Adding to the challenge is that identifying a MET fusion gene requires not only testing for MET, but testing in a very specific way.
In this case, researchers used nifty chemistry to attach gold nanoparticles to antibodies (because, gold nanoparticles).
“We’ve done it. We’ve finally done it. We’ve finally shown this is important,” Lyons says.
Carver, a 2-year-old Coloradan battling cancer, is currently in remission thanks to an experimental drug.
Making a difference is what Robinson and Havlick are all about, according to race director Johannes Schmidt, a volunteer like all those in the race organization.
In short, the answer is yes – a deeper initial response leads to a longer overall response.
The endowed chair in esophageal cancer was made possible by the Rady’s gift of $3.15 million.
These cells, which have characteristics of stem cells, often survive treatment to drive or even restart cancer growth.
Lieu will lead CU Cancer Center’s efforts in further developing an Investigator-Initiated Trials Committee.
Congratulations to Dr. Lyons and her team!
“It was like night and day,” Kofel said. “He said, ‘Yes, you have metastatic cancer, but it’s a very solvable, meaning controllable, issue. … It’s very treatable.’ ”
It is also the role of NCCN Guidelines panels to interpret the results of clinical trials through the lens of their own experience and expertise.
"There are factors that favor preoperative immune modulations, such as the potential for downstaging and de-intensification of radiation therapy and chemoradiation therapy," Dr Jimeno said.
"Epacadostat plus nivolumab was active in phase 2 melanoma and squamous cell carcinoma of the head and neck cohorts," said study coauthor Karl D. Lewis, M.D
Seventeen patients were enrolled in the study with a median age of 75 years and 14 with metastatic disease.
One of our long-term patients is in college now and is studying to go on to nursing school as a result of her experience,” Gore says.
The primary endpoint of the study was progression free survival (PFS), the time that a patient can live with a cancer without it getting worse.
Overall survival was median 5.9 months for the two-drug combination and 9.6 months with the addition of vemurafenib.
D. Ross Camidge, MD, PhD, has been instrumental in the development and testing of next-generation ALK-inhibitors against ALK-positive non-small cell lung cancer.
Patients with castration resistant prostate cancer (CRPC) usually have a poor prognosis. In part, this is due to the cancer's ability to resist anti-androgen therapy.
Although she researched bacteria and plant genomics, she wanted to get back into the cancer field after earning her doctorate.
Barb Helfrich and Isabel Schlaepfer: honorees of celebrating 25 years of service in CU medicine.
Dr. Hirsch has been instrumental in prioritizing and elevating mesothelioma research within IASLC and its membership.
MUTATED SF3B1 MAY IMPROPERLY ASSEMBLE GENES FOR EXPRESSION
"I never thought it would be me with colon cancer at 25-years-old," said Brant. "They just thought it might be colitis or irritable bowel syndrome."
The DigniCap was recently approved for use by the FDA. The cap connects to a machine that monitors the cap’s temperature.
Six center: 351 patient study suggests best order of treatment for brain metastases in EGFR lung cancer
"It is an umbrella grant that provides infrastructure, at least partial infrastructure, for supportive clinical trials," Dr. Anthony Elias said.
CU researchers explore how improving fitness and body camposition can impact life for cancer survivors.
Jerry Williams has no big plans for his future. And he likes it that way.
“Based on what we’re learning, the microbiome has astounding potential. We see opportunity and we just need to drive it ahead.”
Clinical trials have proven the power of immunotherapies targeting PD-L1 or PD-1 in a range of cancers
The Broncos singled him out, bringing him a signed football and four tickets to the Broncos-Raiders game on New Year’s Day.
Ross Camidge MD, has joined a short list of lung cancer experts honored with the “A Breath Away from the Cure” Award.
“It is important to spread the message that lung cancer affects everyone: young and old, rich and poor, smoker and non-smoker."
Ellen March credits her breast cancer diagnosis to an unlikely source – her infant twins.
“This money can really help jumpstart early stage investigator’s careers and thereby ensure the future of cancer research,” says Richer.
Cancer does not discriminate. Sometimes it chooses the young and the healthy, and while cancer may take a life, it can never take away the gift that some choose to leave behind.
It’s a success in new medicine that medical experts hope will continue in the ongoing fight against not just ovarian cancer, but all forms of cancer.
“SOX2 and aldehyde inhibitors are now under exploration, and we’ve also done trials of early PI3K inhibitors here at CU Cancer Center,” Jimeno says.